Cannabix Technologies Inc (BLOZF)

[shell3]

PITTCON 2017 & NEW Marijuana ETF Fund - BLO/ZF

Sorry but I only get (1) Sticky so here's (2) Things of Interest

(1)
BLOZF in NYSE - ETF Emerging AgroSphere Fund

Cannabix is Listed in the 1st Marijuana ETF Fund
https://www.newcannabisventures.com/first-cannabis-etf-in-the-works-emerging-agrosphere/

And the Filing of the New Fund https://www.sec.gov/Archives/edgar/data/1467831/000114420417009539/v459698_485apos.htm

The current sixty-nine constituents include:

22nd Century Group, Abattis Bioceuticals, Abbott Laboratories, Abbvie, Aero Grow Intl, Affinor Growers, Agritek Holdings, American Cannabis Company, Americann, Aphria, Arrow Electronics, Aurora Cannabis, Axim Biotechnologies, Beleave, Cannabics Pharmaceuticals, Cannabis Sativa, Cannabis Science, Cannabix Technologies, Cannagrow Holdings, Canopy Growth, Cara Therapeutics, Cree, CV Sciences, Easton Pharmaceuticals, Eco Science Solutions, Emblem, Emerald Health Therapeutics, General Cannabis, Golden Leaf Holdings, Green Cures & Botanical Distribution, Greengro Technologies, Growblox Sciences, GW Pharmaceuticals, Heliospectra, Hemp Inc, ICC International Cannabis, Inmed Pharmaceuticals, Insys Therapeutics, Kaya Holdings, Kush Bottles, Maple Leaf Green World, Marapharm Ventures, Marijuana Company Of America, Massroots, mCig, Medical Marijuana Inc, Medicine Man Technologies, Mentor Capital, Naturally Splendid Enterprises, New Colombia Resources, Novus Acquisition & Development, Nutritional High, Organigram, OWC Pharmaceutical, Pharmacan Capital, Pharmacyte Biotech, Rocky Mountain High Brands, Scotts Miracle-Gro, Signal Bay, Supreme Pharmaceuticals, Surna, Terra Tech, Tetra Bio-Pharma, THC Biomed, Trailblazer Resources, United Cannabis Corp, Veritas Pharma, Vodis Pharmaceuticals and Zynerba Pharmaceuticals.

(2)
PITTCON CONFERENCE & EXPO 2017 McCormick Place Chicago, IL, USA

Lovely Post AMG
and
I couldn't help but
Notice Cannabix Technologies Inc Listed Here

Posted by: AMG
In reply to: None Date:1/13/2017 2:05:33 PM
Post #698 of 701

PITTCON CONFERENCE & EXPO 2017 McCormick Place Chicago, IL, USA
https://ca.pittcon.org/Technical%20Program/tpabstra17.nsf/focus/13EB647AAA156C048525800B006D8D56?opendocument&nav=keyword&cat=Biomedical




ABSTRACT

Basic Information

Abstract Number: 2440 - 7
Author Name: Michael T Costanzo - Breathtec Biomedical
Session Title: Metabolomics: Breath as a Sample for Clinical Analysis
Event Type: Symposia
Event Title: Towards Point-of-Care Diagnostic Screening for Breath Analysis Using FAIMS and FAIMS/MS

Presider Name: Richard A Yost Co-Author: Michael S Wei, Jared J Boock, Richard A Yost
Affiliation: University of Florida Affiliation: University of Florida, Cannabix Technologies Inc.

Date: Thursday, March 9, 2017
Start Time: 04:10 PM (Slot #7)
Location: W179b

Abstract Content

Since its inception, field asymmetric ion mobility spectrometry (FAIMS) has been envisioned as a field-portable device, as it affords less expense and greater simplicity than many similar methods. Portable FAIMS could provide in situ analysis, allowing researchers to bring the lab to the sample. Ideally, these are simple, robust devices that may be operated by non-professional personnel, yet still provide adequate data when in the field. While reducing the size and complexity tends to bring with it a loss of performance and accuracy, this is made up for by the incredibly high throughput and overall portability of the instrument. Moreover, the point-of-care (POC) FAIMS device can be brought back to the lab and coupled to a conventional mass spectrometer to provide the necessary method development and compound validation. However, to realize such a device, several considerations for miniaturization of the instrumentation must be discussed, as well as how the future of various applications may benefit from the development and acceptance of POC FAIMS.

In preliminary studies, numerous standards were analyzed by both home-built and commercially available FAIMS systems. Several components necessary for a miniaturized POC FAIMS device are currently under development; notably, a novel asymmetric square-waveform generator that is responsible for separation of ions by FAIMS, and a standalone detector which allows the FAIMS device to operate without the need for a mass spectrometer. These components were tested for function, efficiency, and reliability, and the data will be presented here.




/////AMG